Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

APTO has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, February 12th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $130.00.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $2.98 on Wednesday. Aptose Biosciences has a 1 year low of $2.39 and a 1 year high of $54.56. The firm has a fifty day moving average price of $5.64 and a 200-day moving average price of $8.54. The company has a market cap of $6.38 million, a price-to-earnings ratio of -1.00 and a beta of 0.88.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp lifted its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.